Zevra Therapeutics Sees Rare-Disease Market as $30M+ Per-Quarter Opportunity

Zevra Therapeutics (ZVRA) highlighted its expanding pipeline and market potential at Morgan Stanley’s 24th Annual Global Healthcare Conference on September 14, 2026, projecting the rare-disease sector as a lucrative growth area. The company’s lead therapy, MIPLYFFA (arimoclomol), is designed to treat Niemann-Pick disease type C (NPC), a condition previously misdiagnosed as childhood Alzheimer’s or multiple sclerosis, with recent data revealing that about 50% of newly identified patients are adults—a shift management had not anticipated a year prior. As of the end of Q2, Zevra reported $260 million in cash reserves and 132 patients in its global expanded access program, with 66 patients enrolled in a Phase III trial for vascular Ehlers-Danlos syndrome (vEDS), a subset of 7,500 estimated U.S. patients lacking FDA-approved treatment options. The company’s revenue grew 119% year-over-year to $136 million in the past 12 months, with quarterly earnings of $0.96 per share and a 95% gross profit margin, underscoring its debt-free status after repaying high-interest debt through asset monetization. MIPLYFFA has generated roughly $30 million per quarter since its launch, though its international expansion often follows U.S. wholesale acquisition cost pricing. Open-label data for MIPLYFFA show disease progression halted within 12 months on the Niemann-Pick disease type C Clinical Severity Scale when combined with miglustat, a treatment originally approved over a decade ago. The company also submitted pediatric investigational plans to the European Medicines Agency (EMA) and updated clinical guidelines support its combination therapy approach. Regulatory timelines remain critical: the EMA is expected to provide clarity on arimoclomol’s re-examination by the fourth quarter of 2024, while Zevra plans to re-engage with the FDA on celiprolol acceleration strategies in the second half of 2024. Analysts project Zevra stock to rise from its current trading range of $11.95–$12.05 to between $20 and $35, reflecting its expanding patient base and pipeline potential.